BRUSSELS, Jan 22 (Reuters) - EU regulators extended on Friday their review of U.S. drugmaker Abbott Laboratories’ (ABT.N) plan to acquire Belgian peer Solvay Pharmaceuticals (SOLB.BR) after Abbott offered remedies to ease competition concerns.
The European Commission, competition watchdog of the 27-country European Union, said in its daily list of mergers under review that it would decide on the deal by Feb. 11. The previous deadline was Jan. 28.
It gave no further details. (Reporting by Foo Yun Chee, editing by Dale Hudson)